JAK1-selective kinase inhibitor

in clinical development for cancer

from HTS and SBDD of promiscuous hit

J. Med. Chem., Apr. 28, 2020

AstraZeneca, Waltham, MA


AZD4205 is a JAK1-selective kinase inhibitor which is in clinical development for oncology rather than the inflammatory diseases most JAK1 inhibitors have aimed for. The compound has excellent PK in…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: